KR20220029717A - 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템 - Google Patents

항암 화합물 e7766의 치료 순응도 향상을 위한 시스템 Download PDF

Info

Publication number
KR20220029717A
KR20220029717A KR1020227003441A KR20227003441A KR20220029717A KR 20220029717 A KR20220029717 A KR 20220029717A KR 1020227003441 A KR1020227003441 A KR 1020227003441A KR 20227003441 A KR20227003441 A KR 20227003441A KR 20220029717 A KR20220029717 A KR 20220029717A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
patient
administration
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227003441A
Other languages
English (en)
Korean (ko)
Inventor
롱롱 지앙
바이샬리 딕시트
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20220029717A publication Critical patent/KR20220029717A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227003441A 2019-07-01 2020-07-01 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템 Pending KR20220029717A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869389P 2019-07-01 2019-07-01
US62/869,389 2019-07-01
PCT/US2020/040515 WO2021003279A1 (en) 2019-07-01 2020-07-01 System for enhancing therapeutic compliance of the anti-cancer compound e7766

Publications (1)

Publication Number Publication Date
KR20220029717A true KR20220029717A (ko) 2022-03-08

Family

ID=71895194

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003441A Pending KR20220029717A (ko) 2019-07-01 2020-07-01 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템

Country Status (10)

Country Link
US (1) US12564600B2 (https=)
EP (1) EP3993809B1 (https=)
JP (1) JP7704690B2 (https=)
KR (1) KR20220029717A (https=)
CN (1) CN114599374A (https=)
AU (1) AU2020300543A1 (https=)
BR (1) BR112021026876A2 (https=)
CA (1) CA3145824A1 (https=)
MX (1) MX2022000052A (https=)
WO (1) WO2021003279A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024533394A (ja) 2021-09-09 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｓｔｉｎｇアゴニストのバイオマーカー及びその使用方法
CN115512788B (zh) * 2022-09-16 2023-08-08 山东大学 预测SGLTi人体暴露量及靶蛋白抑制率的方法及系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2446893A1 (en) * 2010-11-01 2012-05-02 Bergen Teknologioverføring AS Use of nontoxic cyclic peptides to block transport via OATP1B1/ OATP1B3-related proteins, for the treatment of cancer cells expressing such transporters
JP2015516423A (ja) 2012-05-07 2015-06-11 ノバルティス アーゲー アリスポリビルによる薬物動態の調節
PL3265565T3 (pl) 2015-03-04 2021-01-25 Board Of Regents, The University Of Texas System Sposoby leczenia nowotworu z hemizygotyczną utratą tp53
JP2019512233A (ja) 2016-03-10 2019-05-16 ザ・ジョンズ・ホプキンス・ユニバーシティー 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
KR102512494B1 (ko) 2017-06-30 2023-03-22 교와 가부시키가이샤 의약
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Also Published As

Publication number Publication date
AU2020300543A1 (en) 2022-02-24
JP2022538898A (ja) 2022-09-06
CN114599374A (zh) 2022-06-07
MX2022000052A (es) 2022-04-06
EP3993809B1 (en) 2024-10-09
EP3993809A1 (en) 2022-05-11
BR112021026876A2 (pt) 2022-02-22
US12564600B2 (en) 2026-03-03
WO2021003279A1 (en) 2021-01-07
US20220304982A1 (en) 2022-09-29
CA3145824A1 (en) 2021-01-07
JP7704690B2 (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
UA110853C2 (uk) Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CN104619345A (zh) 液体制剂
JP7190425B2 (ja) 肝細胞癌の治療のための併用療法
EP1878444A1 (en) Composition containing antidementia agent
HK1204998A1 (en) Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN109414423A (zh) 包含丙戊酸的延迟释放药物制剂和其用途
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
RU2820595C2 (ru) Система для повышения степени соблюдения терапевтической схемы с противораковым соединением e7766
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы
EP3431078B1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000